Repligen Earnings Beat Puts Focus On Analytics Growth And Rich Valuation [Yahoo! Finance]
Repligen Corporation (RGEN)
Last repligen corporation earnings: 2/20 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
repligen.com/investors
Company Research
Source: Yahoo! Finance
Repligen (NasdaqGS:RGEN) reported earnings in which revenue exceeded company guidance. Operating income also came in ahead of the guidance range, supported by organic growth. Management highlighted strong performance in the Analytics and Proteins segments as key drivers. Repligen focuses on bioprocessing technologies that support biologic drug production, an area that continues to attract investment as complex therapies remain a priority for many pharma and biotech companies. The latest results give you a closer look at how core tools and consumables are being used across Analytics and Proteins, which are central to quality control and upstream processing in biomanufacturing. For investors, earnings that surpass both revenue and operating income guidance can offer a clearer read on current demand for Repligen's products rather than just commentary on long term themes. This update may prompt closer attention to segment level trends, especially how organic growth in Analytics a
Show less
Read more
Impact Snapshot
Event Time:
RGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGEN alerts
High impacting Repligen Corporation news events
Weekly update
A roundup of the hottest topics
RGEN
News
- Repligen (RGEN) had its price target raised by HC Wainwright from $180.00 to $208.00. They now have a "buy" rating on the stock.MarketBeat
- Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin [Yahoo! Finance]Yahoo! Finance
- A Look Back at Drug Development Inputs & Services Stocks' Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack [Yahoo! Finance]Yahoo! Finance
- 2 Growth Stocks Set to Flourishand 1 We Turn Down [Yahoo! Finance]Yahoo! Finance
- Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
RGEN
Earnings
- 2/24/26 - Beat
RGEN
Sec Filings
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- RGEN's page on the SEC website